PreprintPDF Available

Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study

Authors:
Preprints and early-stage research may not have been peer reviewed yet.

Abstract and Figures

COVID-19, a new strain of coronavirus (CoV), was identified in Wuhan, China, in 2019. No specific therapies are available and investigations regarding COVID-19 treatment are lacking. Liu et al. (2020) successfully crystallised the COVID-19 main protease (Mpro), which is a potential drug target. The present study aimed to assess bioactive compounds found in medicinal plants as potential COVID-19 Mpro inhibitors, using a molecular docking study. Molecular docking was performed using Autodock 4.2, with the Lamarckian Genetic Algorithm, to analyse the probability of docking. COVID-19 Mpro was docked with several compounds, and docking was analysed by Autodock 4.2, Pymol version 1.7.4.5 Edu, and Biovia Discovery Studio 4.5. Nelfinavir and lopinavir were used as standards for comparison. The binding energies obtained from the docking of 6LU7 with native ligand, nelfinavir, lopinavir, kaempferol, quercetin, luteolin-7-glucoside, demethoxycurcumin, naringenin, apigenin-7-glucoside, oleuropein, curcumin, catechin, epicatechin-gallate, zingerol, gingerol, and allicin were -8.37, -10.72, -9.41, -8.58, -8.47, -8.17, -7.99, -7.89, -7.83, -7.31, -7.05, -7.24, -6.67, -5.40, -5.38, and -4.03 kcal/mol, respectively. Therefore, nelfinavir and lopinavir may represent potential treatment options, and kaempferol, quercetin, luteolin-7-glucoside, demethoxycurcumin, naringenin, apigenin-7-glucoside, oleuropein, curcumin, catechin, and epicatechin-gallate appeared to have the best potential to act as COVID-19 Mpro inhibitors. However, further research is necessary to investigate their potential medicinal use.
Content may be subject to copyright.
Article
Potential Inhibitor of COVID-19 Main Protease (Mpro)
from Several Medicinal Plant Compounds by
Molecular Docking Study
Siti Khaerunnisa 1,*, Hendra Kurniawan 2,3, Rizki Awaluddin 4, Suhartati Suhartati5, Soetjipto
Soetjipto 1,*
1 Departement of Medical Biochemistry, Faculty of Medicine, Airlangga University, Surabaya, East Java,
Indonesia, 60132; st.khaerunnisa@fk.unair.ac.id; soetjipto@fk.unair.ac.id
2 Departement of Medical and Surgical Nursing, Faculty of Health Science, University of Muhammadiyah
Jember, Jember, East Java, Indonesia, 68121; hendrakurniawan@unmuhjember.ac.id
3 PhD Student, Tropical Disease Research Center, Faculty of Medicine. Khon Kaen University, Khon Kaen,
Thailand, 40002; hendrakurniawan@unmuhjember.ac.id
4 Departement of Pharmacy, Faculty of Health Science, University of Darussalam Gontor, Ponorogo, East
Java, Indonesia, 63471; awaluddinrizki@gmail.com
5 Departement of Medical Biochemistry, Faculty of Medicine, University of Wijaya Kusuma Surabaya, East
Java, Indonesia, 60225; tati_biokim@yahoo.co.id
* Correspondence: st.khaerunnisa@fk.unair.ac.id ; Tel.: +6281233118194 (S.K.); soetjipto@fk.unair.ac.id;
Tel.: +6281331340518 (S.S.); hendrakurniawan@unmuhjember.ac.id ; Tel.: +628113572277 (H.K.)
Abstract: COVID-19, a new strain of coronavirus (CoV), was identified in Wuhan, China, in 2019.
No specific therapies are available and investigations regarding COVID-19 treatment are lacking.
Liu et al. (2020) successfully crystallised the COVID-19 main protease (Mpro), which is a potential
drug target. The present study aimed to assess bioactive compounds found in medicinal plants as
potential COVID-19 Mpro inhibitors, using a molecular docking study. Molecular docking was
performed using Autodock 4.2, with the Lamarckian Genetic Algorithm, to analyse the probability
of docking. COVID-19 Mpro was docked with several compounds, and docking was analysed by
Autodock 4.2, Pymol version 1.7.4.5 Edu, and Biovia Discovery Studio 4.5. Nelfinavir and lopinavir
were used as standards for comparison. The binding energies obtained from the docking of 6LU7
with native ligand, nelfinavir, lopinavir, kaempferol, quercetin, luteolin-7-glucoside,
demethoxycurcumin, naringenin, apigenin-7-glucoside, oleuropein, curcumin, catechin,
epicatechin-gallate, zingerol, gingerol, and allicin were -8.37, -10.72, -9.41, -8.58, -8.47, -8.17, -7.99, -
7.89, -7.83, -7.31, -7.05, -7.24, -6.67, -5.40, -5.38, and -4.03 kcal/mol, respectively. Therefore, nelfinavir
and lopinavir may represent potential treatment options, and luteolin-7-glucoside,
demethoxycurcumin, apigenin-7-glucoside, oleuropein, curcumin, catechin, and epicatechin-gallate
appeared to have the best potential to act as COVID-19 Mpro inhibitors. However, further research
is necessary to investigate their potential medicinal use.
Keywords: COVID-2019; Mpro; 6LU7; Medicinal Plant Compounds; Docking
1. Introduction
Coronaviruses (CoVs) are an etiologic agent of severe infections in both humans and animals,
which can cause disorder not only in the respiratory tract but also in the digestive tract and
systemically. Previous studies of CoVs have reported that CoVs can infect certain species of animals,
including mammals, avian species, and reptiles [1].
The new strain of CoV was identified at the end of 2019, initially named 2019-nCoV, and
emerged during an outbreak in Wuhan, China [2]. The Emergency Committee of the World Health
Organization (WHO) declared an outbreak in China on January 30, 2020, which was considered to be
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
© 2020 by the author(s). Distributed under a Creative Commons CC BY license.
2 of 14
a Public Health Emergencies of International Concern (PHEIC) [3]. Officially, WHO named this CoV
COVID-19 (coronavirus disease 2019), on February 11, 2020, based on consultations and
collaborations with the World Organization for Animal Health and the Food and Agriculture
Organization of the United Nations [4].
According to the current situational report from WHO, released on February 11, 2020, 43,103
COVID-19 cases have been confirmed globally, including 2,560 new cases. In China, the number of
confirmed cases reached 42,708, including 2,484 new cases, 7,333 severe cases, and 1,017 deaths.
Outside of China, 395 cases were confirmed in 24 countries, with 1 death [4].
Currently, no specific therapies for COVID-19 are available and investigations regarding the
treatment of COVID-19 are lacking [3]. However, the measures that have been implemented remain
limited to preventive and supportive therapies, designed to prevent further complications and organ
damage [3]. Some preliminary studies have investigated potential combinations that include the
protease inhibitor lopinavir/ritonavir, which is commonly used to treat human immunodeficiency
virus (HIV)/acquired immunodeficiency syndrome patients, for the treatment of COVID-19-infected
patients [5]. Other reported antiviral treatments form human pathogenic CoVs include nucleoside
analogues, neuraminidase inhibitors, remdesivir, umifenovir (arbidol), tenofovir disoproxil (TDF),
and lamivudine (3TC) [5]. A separate investigation performed by Xu et al. (2020) indicated that
among 4 tested drugs (nelfinavir, pitavastatin, perampanel, and praziquantel), nelfinavir was
identified as the best potential inhibitor against COVID-19 Mpro, based on binding free energy
calculations using the molecular mechanics with generalised Born and surface area solvation
(MM/GBSA) model and solvated interaction energy (SIE) methods [6].
The results from preliminary studies remain unapproved for therapeutic use in clinical settings
for the treatment of COVID-19-infected patients [5, 7]. Liu et al. (2020) have successfully crystallised
the main protease (Mpro)/chymotrypsin-like protease (3CLpro) from COVID-19, which has been
structured and repositioned in the Protein Data Bank (PDB) and is accessible by the public. This
protease represents a potential target for the inhibition of CoV replication [6].
Environmental factors can greatly influence the secretion of secondary metabolites from tropical
plants. Therefore, great attention has been paid to the secondary metabolites secreted by plants in
tropical regions that may be developed as medicines [8, 9]. Several compounds, such as flavonoids,
from medicinal plants, have been reported to have antiviral bioactivities [1012]. In the present study,
we investigated kaempferol, quercetin, luteolin-7-glucoside, demethoxycurcumin, naringenin,
apigenin-7-glucoside, oleuropein, curcumin, catechin, epicatechin-gallate, zingerol, gingerol, and
allicin as potential inhibitor candidates for COVID-19 Mpro. The findings of the present study will
provide other researchers with opportunities to identify the right drug to combat COVID-19.
2. Experimental Section
Proteins/Macromolecules
COVID-19 3clpro/Mpro (PDB ID: 6LU7) [13] and 3clpro/Mpro (PDB ID: 2GTB) [6] structures were
obtained from PDB (https://www.rcsb.org/), in .pdb format. PDB is an archive for the crystal
structures of biological macromolecules, worldwide [33].
The 6LU7 protein contains two chains, A and B, which form a homodimer. Chain A was used
for macromolecule preparation. The native ligand for 6LU7 is n-[(5-methylisoxazol-3-
yl)carbonyl]alanyl-l-valyl-n~1~-((1r,2z)-4-(benzyloxy)-4-oxo-1-{[(3r)-2-oxopyrrolidin-3-
yl]methyl}but-2-enyl)-l-leucinamide.
Ligand and Drug Scan
The 3-dimensional (3D) structures were obtained from PubChem
(https://pubchem.ncbi.nlm.nih.gov/), in .sdf format. PubChem is a chemical substance and biological
activities repository consisting of three databases, including substance, compound, and bioassay
databases [34]. Several ligands for which the active compound can be found in herbal medicine were
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
3 of 14
downloaded from Dr. Duke’s Phytochemical and Ethnobotanical Databases
(https://phytochem.nal.usda.gov/phytochem/search/list). The compounds used in the present study
were nelfinavir (CID_64143), lopinavir (CID_92727), luteolin-7-glucoside (CID_5280637),
demethoxycurcumin (CID_5469424), apigenin-7-glucoside (CID_5280704), oleuropein
(CID_56842347), curcumin (CID_969516), epicatechin-gallate (CID_107905), zingerol (CID_3016110),
gingerol (CID_442793), catechin (CID_9064), and allicin (CID_65036), quercetin (CID_5280343),
kaempferol (CID_5280863) and naringenin (CID_439246).
Drug-like properties were calculated using Lipinski’s rule of five, which proposes that molecules
with poor permeation and oral absorption have molecular weights > 500, C logP > 5, more than 5
hydrogen-bond donors, and more than 10 acceptor groups [16, 17] Adherence with Lipinski’s rule of
five as calculated using SWISSADME prediction (http://www.swissadme.ch/).
Determination of Active Sites
The amino acids in the active site of a protein were determined using the Computed Atlas for
Surface Topography of Proteins (CASTp) (http://sts.bioe.uic.edu/castp/index.html?201l) and Biovia
Discovery Studio 4.5. The determination of the amino acids in the active site was used to analyse the
Grid box and docking evaluation results. Discovery Studio is an offline life sciences software that
provides tools for protein, ligand, and pharmacophore modelling [18].
Molecular Docking
Ligand optimisation was performed by Avogadro version 1.2, with Force Field type MMFF94,
and saved in .mol2 format. Autodock version 4.2 used for protein optimisation, by removing water
and other atoms, and then adding a polar hydrogen group. Autodock 4.2 was supported by Autodock
tools, MGL tools, and Rasmol. Autogrid then determined the native ligand position on the binding
site by arranging the grid coordinates (X, Y, and Z). Ligand tethering of the protein was performed
by regulating the genetic algorithm (GA) parameters, using 10 runs of the GA criteria. The docking
analyses were performed by both Autodock 4.2, Pymol version 1.7.4.5 Edu and Biovia Discovery
Studio 4.5.
3. Results
Table 1 shows the structures and amino acids found in the active site pockets of 6LU7 and 2GTB.
6LU7 is the main protease (Mpro) found in COVID-19, which been structured and repositioned in PDB
and can be accessed by the public, as of early February 2020.
2GTB is the main protease found in the CoV associated with the severe acute respiratory
syndrome (SARS), which can be accessed in PDB and was suggested to be a potential drug target for
2019-nCov [6]. Xu et al. (2020) mentioned that the main protease in 2019-nCov shares 96% similarity
with that in SARS.
Table 1. Protein target structures and active site amino acids (Biovia Discovery Studio 4.5,
2019) and the native ligand structure
No
PDB
ID
Macromolecule
Native Ligand
Active site
1
6LU7
THR24, THR26, PHE140,
ASN142, GLY143, CYS145,
HIS163, HIS164, GLU166,
HIS172
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
4 of 14
2
2GTB
LYS5, ALA7, THR25, HIS41,
MET49, TYR54, VAL125,
TYR126, GLY127, PHE140,
LEU141, ASN142, GLY143,
SER144, CYS145, HIS163,
HIS164, MET165, GLU166,
LEU167, PRO168, HIS172,
ASP187, ARG188, GLN189,
GLN192, ALA198, LYS236,
TYR237, GLN273
Ligands and several drug candidate compounds have been previously selected, based on
adherence to Lipinski’s rule of five. The selected ligands that did not incur more than 2 violations of
Lipinski’s rule could be used in molecular docking experiments with the target protein. The drug
scanning results (Table 2) show that all tested compounds in this study were accepted by Lipinski’s
rule of five.
Table 2. Properties of COVID-19 Mpro potential inhibitor candidates
No
Compound
Molecular structure and
Interaction with 6LU7
Lipinski’s rule of five
Properties
Value
1
Lopinavir
Molecular weight (<500
Da)
628.8
LogP (<5)
4.37
H-Bond donor (5)
4
H-bond acceptor (<10)
5
Violations
1
2
Nelfinavir
Molecular weight (<500
Da)
567.78
LogP (<5)
4.33
H-Bond donor (5)
4
H-bond acceptor (<10)
5
Violations
1
3
Luteolin-7-
glucoside
Molecular weight (<500
Da)
448.38
LogP (<5)
0.16
H-Bond donor (5)
7
H-bond acceptor (<10)
11
Violations
2
4
Demethoxycur
cumin
Molecular weight (<500
Da)
338.35
LogP (<5)
3
H-Bond donor (5)
2
H-bond acceptor (<10)
5
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
5 of 14
Violations
0
5
Apigenin-7-
glucoside
Molecular weight (<500
Da)
432.34
LogP (<5)
0.55
H-Bond donor (5)
6
H-bond acceptor (<10)
10
Violations
1
6
Oleuropein
Molecular weight (<500
Da)
378.37
LogP (<5)
1.57
H-Bond donor (5)
3
H-bond acceptor (<10)
8
Violations
0
7
Epicatechin-
gallate
Molecular weight (<500
Da)
442.37
LogP (<5)
1.23
H-Bond donor (5)
7
H-bond acceptor (<10)
10
Violations
1
8
Catechin
Molecular weight (<500
Da)
290.27
LogP (<5)
0.85
H-Bond donor (5)
5
H-bond acceptor (<10)
6
Violations
0
9
Curcumin
Molecular weight (<500
Da)
368.38
LogP (<5)
3.03
H-Bond donor (5)
2
H-bond acceptor (<10)
6
Violations
0
10
Zingerol
Molecular weight (<500
Da)
196.24
LogP (<5)
1.86
H-Bond donor (5)
2
H-bond acceptor (<10)
3
Violations
0
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
6 of 14
11
Gingerol
Molecular weight (<500
Da)
294.39
LogP (<5)
3.13
H-Bond donor (5)
2
H-bond acceptor (<10)
4
Violations
0
12
Allicin
Molecular weight (<500
Da)
162.27
LogP (<5)
1.61
H-Bond donor (5)
0
H-bond acceptor (<10)
1
Violations
0
13
Kaempferol
Molecular weight (<500
Da)
286,24
LogP (<5)
1,58
H-Bond donor (5)
4
H-bond acceptor (<10)
6
Violations
0
14
Quercetin
Molecular weight (<500
Da)
302,24
LogP (<5)
1,23
H-Bond donor (5)
5
H-bond acceptor (<10)
7
Violations
0
15
Naringenin
Molecular weight (<500
Da)
272,25
LogP (<5)
1,84
H-Bond donor (5)
3
H-bond acceptor (<10)
5
Violations
0
Table 3 shows the molecular docking analysis results for several compounds against 6LU7,
including binding energy/Gibbs Energy, ligand efficiency, inhibition constant, intermolecular energy,
and van der Waals (VDW)-H Bond desolvation energy.
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
7 of 14
Table 3. Molecular docking analysis of several compounds against 6LU7
Protein
Ligand Properties
Binding
Energy
(ΔG)
Ligand
Efficienc
y
Inhibition
Constant
Intermole
cular
Energy
VDW-H Bond
Desolvation
Energy
6LU7
Native Ligand
-8.37
-0.17
736.89 µM
-14.33
-14.33
Nelfinavir
-10.72
-0.27
13.91 nM
-14.3
-13.83
Lopinavir
-9.41
-0.2
126.76 µM
-14.18
-13.83
Kaempferol
-8,58
-0,41
516,02 nM
-10,07
-9,88
Quercetin
-8,47
-0,39
618,19 nM
-10,26
-10,06
Luteolin-7-
glucoside
-8.17
-0.26
1.03 µM
-11.45
-11.38
Demetoxycurcumin
e
-7.99
-0.32
1.38 µM
-10.68
-10.59
Naringenin
-7,89
-0,39
1,64 uM
-9,09
-8,97
Apigenine-7-
glucoside
-7.83
-0.25
1.81 µM
-10.82
-9.92
Oleuropein
-7.31
-0.27
4.4 µM
-10.59
-10.28
Catechin
-7.24
-0.34
4.95 µM
-9.03
-8.78
Curcumin
-7.05
-0.26
6.82 µM
-10.03
-9.88
Epicatechin-gallate
-6.67
-0.21
13.0 µM
-9.95
-9.51
Zingerol
-5.40
-0.38
112.22 µM
-7.18
-7.1
Gingerol
-5.38
-0.26
113.91 µM
-8.96
-8.82
Allicin
-4.03
-0.45
1.11 mM
-5.52
-5.51
Figure 1. Histogram showing molecular docking results between 6LU7 and several drug candidate
compounds (the binding energy value ΔG is shown in minus kcal/mol)
0
2
4
6
8
10
12
ΔG (-kcal/mol)
Compounds
Native Ligand
Nelfinavir
Lopinavir
Kaempferol
Quercetin
Luteolin-7-glucoside
Demethoxycurcumine
Naringenin
Apigenine-7-glucoside
Oleuropein
Catechin
Curcumin
Epicatechin gallate
Zingerol
Gingerol
Allicin
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
8 of 14
Figure 2. Docking analysis visualisation of 6LU7 binding with nelfinavir (A), lopinavir (B), luteolin-
7-glucoside (C), apigenin-7-glucoside (D), oleuropein (E), demethoxycurcumin (F), curcumin (G),
catechin (H), epicatechin-gallate (I), quercetin (J), kaempferol (K) and naringenin (L) using Pymol.
The yellow dots show H-bonds.
Figure 2 (A to I) visualises the binding between 6LU7 and several compounds, including
nelfinavir, lopinavir, luteolin-7-glucoside, apigenin-7-glucoside, oleuropein, demethoxycurcumin,
curcumin, catechin, epicatechin-gallate, quercetin, kaempferol, and naringenin as potential inhibitor
of COVID-19 Mpro.
4. Discussion
Coronaviruses (CoVs) belong to a group of viruses that can infect humans and vertebrate
animals. CoV infections affect the respiratory, digestive, liver, and central nervous systems of humans
and animals [19]. The present study focused on the main proteases in CoVs (3CLpro/Mpro), especially
PDB ID 6LU7, as potential target proteins for COVID-19 treatment. 6LU7 is the Mpro in COVID-19
A
B
C
D
E
F
G
H
I
J
K
L
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
9 of 14
that has been structured and repositioned in PDB and has been accessible by the public since early
February 2020. The Mpro of 2019-nCov shares 96% similarity with the Mpro of the SARS-CoV [6, 20].
The Mpro in CoV is essential for the proteolytic maturation of the virus and has been examined as a
potential target protein to prevent the spread of infection by inhibiting the cleavage of the viral
polyprotein [13]. The discovery of the Mpro protease structure in COVID-19 provides a great
opportunity to identify potential drug candidates for treatment.
Proteases represent potential targets for the inhibition of CoV replication, and the protein
sequences of the SARS-CoV Mpro and the 2019-nCoV Mpro are 96% identical, and the active sites in
both proteins remain free from mutations. The Mpro amino acids Thr24, Thr26, and Asn119 are
predicted to play roles in drug interactions [21]. The disruption of protease activity can lead to various
diseases; thus, commonly, host proteases can be used as potential therapeutic targets. In many viruses,
proteases play essential roles in viral replication; therefore, proteases are often used as protein targets
during the development of antiviral therapeutics [22].
Nelfinavir and lopinavir are protease inhibitors with high cytotoxic values against cells infected
with HIV. Lopinavir and ritonavir are protease inhibitors recommended for the treatment of SARS
and MERS, which have similar mechanisms of action as HIV [23]. The antiviral effects of nelfinavir
against CoV have been studied in vitro, in Vero cells infected with SARS-CoV [24]. The IC50 value for
nelfinavir in SARS-CoV is 0.048 µM [25]. In the present study, we used nelfinavir and lopinavir as
drug standards for comparison.
Several compounds, such as flavonoids, from medicinal plants, have been reported to show
antiviral bioactivities [1012]. We investigated kaempferol, quercetin, luteolin-7-glucoside,
demethoxycurcumin, naringenin, apigenin-7-glucoside, oleuropein, curcumin, catechin, epicatechin-
gallate, zingerol, gingerol, and allicin as potential inhibitors of the COVID-19 Mpro. An in silico
analysis study showed that the compounds share a similar pharmacophore as nelfinavir. Several
studies have investigated the presence of high numbers of these phenolic compounds belonging
several medicinal plant which abundant in nature (see Table 4).
The binding energies obtained from docking 6LU7 with the native ligand, nelfinavir, lopinavir,
kaempferol, quercetin, luteolin-7-glucoside, demethoxycurcumin, naringenin, apigenine-7-glucoside,
oleuropein, curcumin, catechin, epicatechin-gallate, zingerol, gingerol, and allicin were -8.37, -10.72,
-9.41, -8.58, -8.47,-8.17, -7.99, -7.89, -7.83, -7.31, -7.05, -7.24, -6.67, -5.40, -5.38, -5.40, and -4.03 kcal/mol,
respectively (see Table 3 and Figure 1).
Table 4. Source of several compounds belong to medicinal plants
Compounds
Sources
Species name
Reference
Kaempferol
Spinach
Spinacia oleracea
[26]
Cabbage
Brassica oleracea
[26]
Dill
Anethum graveolens
[26]
Chinese cabbage
Brassica rapa
[26]
Katuk
Sauropus androgynus
[27]
Quercetin
Dill
Anethum graveolens
[26]
Fennel leaves
Foeniculum vulgare
[26]
Onion
Allium cepa
[26]
Oregano
Oregano vulgare
[26]
Chili pepper
Capsicum annum
[26]
Luteolin-7-glucoside
Olive
Olea Europaea L
[2830]
Star fruit
Averrhoa belimbi
[31]
Chili pepper
Capsicum annum
[31]
Welsh onion /
Leek
Allium fistulosum
[31]
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
10 of 14
Demethoxycurcumine
Turmeric
Curcuma longa
[32], [33]
Curcuma
Curcuma xanthorriza
[32], [33]
Naringenin
Citrus fruit
Citrus sinensis
[34]
Apigenine-7-glucoside
Star fruit
Averrhoa belimbi
[31]
Goji berries
Lycium chinense
[31]
Celery
Apium graveolens
[31]
Olive
Olea Europaea L
[29], [30]
Oleuropein
Olive
Olea Europaea L
[2830]
Catechin
Green tea
Camellia sinesis
[3537]
Curcumin
Turmeric
Curcuma longa
[3841]
Curcuma
Curcuma xanthorriza
[32], [33]
Epicatechin gallate
Green tea
Camellia sinesis
[3537]
Zingerol
Ginger
Zingiber officiale
[4244]
Gingerol
Ginger
Zingiber officiale
[4244]
Allicin
Garlic
Allium sativum
[4547]
The results of docking analysis (Table 2 and Figure 2) showed that nelfinavir forms H-bonds
with the 6LU7 amino acids Glu166, Gln189, and Gln192 (Figure 2A). Lopinavir forms H-bonds with
the 6LU7 amino acids Glu166, Arg188, and Gln189 (Figure 2B). Luteolin-7-glucoside and forms H-
bonds with the 6LU7 amino acid Phe140, Cys145, His163, His164, and Thr190 (Figure 2C).
Demethoxycurcumin forms H-bonds with the 6LU7 amino acids Phe140, Leu141, Gly143, Ser144,
Cys145, His163, Glu166, and Arg188 (Figure 2D). Apigenin-7-glucoside forms H-bonds with the
6LU7 amino acids Phe140, Cys145, Glu166, Thr190, and Gln192 (Figure 2E). Oleuropein forms H-
bonds with the 6LU7 amino acids Tyr54, Leu141, His163, and Glu166 (Figure 2F). Curcumin forms
H-bonds with the 6LU7 amino acids Leu141, Gly143, Ser144, Cys145, and Thr190 (Figure 2G).
Catechin forms H-bonds with the 6LU7 amino acids His164, Glu166, Asp187, Thr190, and Gln192
(Figure 2H). Epicatechin-gallat forms H-bonds with the 6LU7 amino acids Asn142, His164, Glu166,
and Thr190 (Figure 2I). Quercetin forms H-bonds with the 6LU7 amino acid His164, Glu166, Asp187,
Gln192, Thr190 (Figure 2J). Kaempferol forms H-bonds with the 6LU7 amino acid Tyr54, His164,
Glu166, Apr187, Thr190 (Figure 2J). Naringenin forms H-bonds with the 6LU7 amino acid His164,
Glu166, Asp187, Thr190 (Figure 2J). Docking analysis results, including the H-bonds that interact
with 6LU7 amino acids, can be observed in Table 1. All of the H-bonds interacted with amino acids
in the COVID-19 Mpro active site. The binding energy results are related to the number of H-bonds
formed with the active site pocket of COVID-19 Mpro.
Figure 3. Luteolin-7-glucoside (aglycone) (a) and kaempferol (b) mapped to the pharmacophore
model [48]
(a)
(b)
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
11 of 14
Kaempferol and quercetin are a flavonol compounds, while luteolin-7-glucoside is a flavone
within the class of flavonoid compounds [49]. Secondary metabolite compounds are commonly
found in medicinal plants. Luteolin-7-glucoside and kaempferol shown in Figure 3, is a form of
aglycone of flavonoid. Hydroxy groups (-OH), ketone groups (=O) and ether groups (-O-) in luteolin
and kaempferol compounds are predicted to play roles amino acid residue interactions at the active
site of COVID-19 Mpro [50].
The high affinity of drug compounds depends on the type and amount of bonding that occurs
with the active site of the protein. In Table 2, nelfinavir forms many chemical bonds with 6LU7,
including hydrogen bonds and hydrophobic bonds. Kaempferol, quercetin and luteolin-7-glucoside
also forms many chemical bonds, similar to nelfinavir. Therefore, the affinity of kaempferol bonds is
higher compared with other compounds.
The docking analysis in the present study showed the inhibition potential of several compounds,
ranked by affinity (ΔG); nelfinavir > lopinavir > kaempferol > quercetin > luteolin-7-glucoside >
demethoxycurcumin > naringenin > apigenine-7-glucoside > oleuropein > curcumin > catechin >
epigallocatechin > zingerol > gingerol > allicin.
Kaempferol, quercetin, luteolin-7-glucoside, apigenin-7-glucoside, naringenin, oleuropein,
demethoxycurcumin, curcumin, catechin, and epigallocatechin were the most recommended
compounds found in medicinal plants as potential inhibitors of COVID-19 Mpro, which should be
explored in future research.
5. Conclusions
Currently, COVID-19 has emerged in the human population, in China, and is a potential threat
to global health, worldwide. However, no approved drug currently exists to treat the disease. The
currently available drugs for COVID-19 treatment primarily act on the main protease (Mpro). The aim
of this study was to examine several medicinal plant-derived compounds that may be used to inhibit
the COVID-19 infection pathway. Nelfinavir, lopinavir, kaempferol, quercetin, luteolin-7-glucoside,
demethoxycurcumin, naringenin, apigenin-7-glucoside, oleuropein, curcumin, catechin, and
epicatechin-gallate have the lowest binding energies and inhibition constants. The affinity of
kaempferol bonds is higher compared with other compounds. Therefore, we suggested that
nelfinavir and lopinavir may represent potential treatment options, and kaempferol, quercetin,
luteolin-7-glucoside, demethoxycurcumin, naringenin, apigenin-7-glucoside, oleuropein, curcumin,
catechin, and epicatechin-gallate were the most recommended compounds found in medicinal plants
that may act as potential inhibitors of COVID-19 Mpro. However, further research is necessary to
investigate the potential uses of the medicinal plants containing these compounds.
Author Contributions: This study was conducted and conceptualization by SK, HK, RA, SH, SS ,; methodology
by SK, SH and RA,; installation software by RA,; validation by SK and HK,; formal analysis by RA and SS,;
investigation by HK, SH, and SS,; resources by SK and SS,; data curation by SK, HK and RA,; writing-original draft
preparation by SK, HK and RA,; writing-review and editing by SK, HK, RA, SH and SS,; visualization by SK and SS,;
supervision by HK and RA,; project administration by SK,; funding acquisition by SS. All author have read and areed
to the the published version of the manuscript.
Funding: This research was funded by a Grant-in-Aid from Dato’ Sri Prof. Dr. Tahir for this research, through
The Tahir Professorship Program, Indonesia
Acknowledgments: All the authors acknowledge and thank their respective Universities and for Dato' Sri Prof.
Dr. Tahir for all supporting this research.
Conflicts of Interest: The authors declare no conflict of interest.
References
[1] W. Malik, Yashpal Singh; Sircar, Shubhankar; Bhat, Sudipta; Sharun, Khan; Dhama, Kuldeep; Dadar,
Maryam; Tiwari, Ruchi; Chaicumpa, “Emerging novel Coronavirus (2019-nCoV) - Current scenario,
evolutionary perspective based on genome analysis and recent developments,” Vet. Q., vol. 40, no. 1, pp. 112,
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
12 of 14
2020, doi: 10.1080/01652176.2020.1727993.
[2] P. R. Lee, Ping Ing; Hsueh, “Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-
nCoV,” J. Microbiol. Immunol. Infect., pp. 13, 2020, doi: 10.1016/j.jmii.2020.02.001.
[3] P. Rodríguez-Morales, Alfonso J; MacGregor, Kirsten; Kanagarajah, Sanch; Patel, Dipti; Schlagenhauf,
“Going global Travel and the 2019 novel coronavirus,” Travel Med. Infect. Dis., vol. 33, 2020, doi:
https://doi.org/10.1016/j.tmaid.2020.101578.
[4] World Health Organization (WHO), “Novel Coronavirus ( 2019-nCoV ),” WHO Bull., no. JANUARY, pp.
17, 2020.
[5] H. Lu, “Drug treatment options for the 2019-new coronavirus (2019-nCoV),” Biosci. Trends, 2020, doi:
10.5582/bst.2020.01020.
[6] Z. Xu, C. Peng, Y. Shi, Z. Zhu, K. Mu, and X. Wang, “Nelfinavir was predicted to be a potential inhibitor of
2019-nCov main protease by an integrative approach combining homology modelling , molecular docking and
binding free energy calculation,” vol. 1201, pp. 0–2, 2020.
[7] M. L. Holshue et al., “First Case of 2019 Novel Coronavirus in the United States,” N. Engl. J. Med., 2020, doi:
10.1056/nejmoa2001191.
[8] G. Guerriero et al., “Production of plant secondary metabolites: Examples, tips and suggestions for
biotechnologists,” Genes (Basel)., vol. 9, no. 6, pp. 3446, 2018, doi: 10.3390/genes9060309.
[9] L. Yang, K. S. Wen, X. Ruan, Y. X. Zhao, F. Wei, and Q. Wang, “Response of plant secondary metabolites
to environmental factors,” Molecules, vol. 23, no. 4, pp. 126, 2018, doi: 10.3390/molecules23040762.
[10] H. Zakaryan, E. Arabyan, A. Oo, and K. Zandi, “Flavonoids: promising natural compounds against viral
infections,” Arch. Virol., vol. 162, no. 9, pp. 25392551, 2017, doi: 10.1007/s00705-017-3417-y.
[11] Thayil, M. Seema, and S. P. Thyagarajan, “Pa-9: A flavonoid extracted from plectranthus amboinicus
inhibits HIV-1 protease,” Int. J. Pharmacogn. Phytochem. Res., vol. 8, no. 6, pp. 10201024, 2016.
[12] S. Jo, S. Kim, D. H. Shin, and M. S. Kim, “Inhibition of SARS-CoV 3CL protease by flavonoids,” J. Enzyme
Inhib. Med. Chem., vol. 35, no. 1, pp. 145151, 2020, doi: 10.1080/14756366.2019.1690480.
[13] R. X, Liu; B, Zhang; Z, Jin; H, Yang; Z, “The crytal structure of 2019-nCoV main protease in complex with
an inhibitor N3,” 2020.
[14] H. M. Berman et al., “The protein data bank,” Acta Crystallogr. Sect. D Biol. Crystallogr., vol. 58, no. 6 I, pp.
899907, 2002, doi: 10.1107/S0907444902003451.
[15] S. Kim et al., “PubChem substance and compound databases,” Nucleic Acids Res., vol. 44, no. D1, pp. D1202
D1213, 2016, doi: 10.1093/nar/gkv951.
[16] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and computational approaches
to estimate solubility and permeability in drug discovery and development settings,” Adv. Drug Deliv. Rev., vol.
64, no. SUPPL., pp. 417, 2012, doi: 10.1016/j.addr.2012.09.019.
[17] B. G. Giménez, M. S. Santos, M. Ferrarini, and J. P. Dos Santos Fernandes, “Evaluation of blockbuster drugs
under the rule-of-five,” Pharmazie, vol. 65, no. 2, pp. 148152, 2010, doi: 10.1691/ph.2010.9733.
[18] G. S. B, L. Xavier, and S. Michael, “Molecular Docking Studies on Antiviral Drugs for SARS,” vol. 5, no. 3,
pp. 7579, 2015.
[19] J. Xu, S. Zhao, T. Teng, A. E. Abdalla, and W. Zhu, “Systematic Comparison of Two Animal-to-Human
Transmitted Human Coronaviruses: SARS-CoV-2 and,” 2020, doi: 10.3390/v12020244.
[20] A. Zhavoronkov et al., “Potential 2019-nCoV 3C-like Protease Inhibitors Designed Using Generative Deep
Learning Approaches,” no. February, 2020, doi: 10.26434/CHEMRXIV.11829102.V1.
[21] X. Liu and X.-J. Wang, “Potential inhibitors against 2019-nCoV coronavirus M protease from clinically
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
13 of 14
approved medicines,” J. Genet. Genomics, 2020, doi: 10.1016/j.jgg.2020.02.001.
[22] K. O. Chang, Y. Kim, S. Lovell, A. D. Rathnayake, and W. C. Groutas, “Antiviral drug discovery: Norovirus
proteases and development of inhibitors,” Viruses, vol. 11, no. 2, pp. 114, 2019, doi: 10.3390/v11020197.
[23] J.-Y. Li et al., “The epidemic of 2019-novel-coronavirus,” Microbes Infect., 2019, doi:
10.1016/j.micinf.2020.02.002.
[24] N. Yamamoto et al., “HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus,”
Biochem. Biophys. Res. Commun., vol. 318, no. 3, pp. 719725, 2004, doi: 10.1016/j.bbrc.2004.04.083.
[25] L. E. Hsieh et al., “Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline
coronavirus,” Antiviral Res., vol. 88, no. 1, pp. 2530, 2010, doi: 10.1016/j.antiviral.2010.06.010.
[26] W. M. Dabeek and M. V. Marra, “Dietary quercetin and kaempferol: Bioavailability and potential
cardiovascular-related bioactivity in humans,” Nutrients, vol. 11, no. 10, 2019, doi: 10.3390/nu11102288.
[27] N. Andarwulan, R. Batari, D. A. Sandrasari, B. Bolling, and H. Wijaya, “Flavonoid content and antioxidant
activity of vegetables from Indonesia,” Food Chem., vol. 121, no. 4, pp. 12311235, 2010, doi:
10.1016/j.foodchem.2010.01.033.
[28] A. Lama-Muñoz, M. Del Mar Contreras, F. Espínola, M. Moya, I. Romero, and E. Castro, “Optimization of
oleuropein and luteolin-7-o-glucoside extraction from olive leaves by ultrasound-assisted technology,” Energies,
vol. 12, no. 13, 2019, doi: 10.3390/en12132486.
[29] F. Nicolì et al., “Evaluation of phytochemical and antioxidant properties of 15 Italian olea europaea L.
Cultivar Leaves,” Molecules, vol. 24, no. 10, 2019, doi: 10.3390/molecules24101998.
[30] J. Meirinhos et al., “Analysis and quantification of flavonoidic compounds from Portuguese olive (olea
europaea L.) leaf cultivars,” Nat. Prod. Res., vol. 19, no. 2, pp. 189195, 2005, doi: 10.1080/14786410410001704886.
[31] H. A. Omar, K. Abboud, N. Cheng, K. R. Malekshan, A. T. Gamage, and W. Zhuang, “Miean, K. H., &
Mohamed, S. (2001). Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible
tropical plants.,” J. Agric. food Chem. 49(6), 3106-3112., vol. 18, no. 4, pp. 23152344, 2016, doi:
10.1109/COMST.2016.2554098.
[32] B. Cahyono, J. Ariani, H. Failasufa, M. Suzery, S. Susanti, and H. Hadiyanto, “Extraction of homologous
compounds of curcuminoid isolated from temulawak (Curcuma xanthorriza roxb.) plant,” Rasayan J. Chem., vol.
12, no. 1, pp. 713, 2019, doi: 10.31788/RJC.2019.1213092.
[33] A. Rosidi, A. Khomsan, B. Setiawan, H. Riyadi, and D. Briawan, “Antioxidant potential of temulawak
(Curcuma xanthorrhiza roxb),” Pakistan J. Nutr., vol. 15, no. 6, pp. 556560, 2016, doi: 10.3923/pjn.2016.556.560.
[34] B. Salehi et al., “The therapeutic potential of naringenin: A review of clinical trials,” Pharmaceuticals, vol. 12,
no. 1, pp. 118, 2019, doi: 10.3390/ph12010011.
[35] M. P. M. De Maat, H. Pijl, C. Kluft, and H. M. G. Princen, “Consumption of black and green tea has no effect
on inflammation, haemostasis and endothelial markers in smoking healthy individuals,” Eur. J. Clin. Nutr., vol.
54, no. 10, pp. 757763, 2000, doi: 10.1038/sj.ejcn.1601084.
[36] D. Rahardiyan, “Antibacterial potential of catechin of tea (Camellia sinensis) and its applications,” Food
Res., vol. 3, no. 1, pp. 16, 2019, doi: 10.26656/fr.2017.3(1).097.
[37] R. M. M. De Oliveira, “Quantification of catechins and caffeine from green tea (Camellia sinensis) infusions,
extract, and ready-to-drink beverages,” Food Sci. Technol., vol. 32, no. 1, pp. 163166, 2012, doi: 10.1590/s0101-
20612012005000009.
[38] I. C. Chao, C. M. Wang, S. P. Li, L. G. Lin, W. C. Ye, and Q. W. Zhang, “Simultaneous quantification of three
curcuminoids and three volatile components of curcuma longa using pressurized liquid extraction and high-
performance liquid chromatography,” Molecules, vol. 23, no. 7, 2018, doi: 10.3390/molecules23071568.
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
14 of 14
[39] L. Narain and M. Pradesh-, “ISSN 2230 8407 QUALITATIVE AND QUANTITATIVE PROFILE OF
CURCUMIN FROM ETHANOLIC EXTRACT OF CURCUMA LONGA Soni Himesh *, Patel Sita Sharan , Mishra
K , Nayak Govind , Singhai AK,” Int. Res. J. Pharm., vol. 2, no. 4, pp. 180184, 2011.
[40] W. Pothitirat and W. Gritsanapan, “Quantitative Analysis of Curcumin , Demethoxycurcumin and
Bisdemethoxycurcumin in the Crude Curcuminoid Extract from Curcuma longa in Thailand by TLC-
Densitometry,” Mahidol Univ. J. Pharm. Sci., vol. 32, no. Figure 1, pp. 2330, 2005.
[41] S. Hewlings and D. Kalman, “Curcumin: A Review of Its’ Effects on Human Health,” Foods, vol. 6, no. 10,
p. 92, 2017, doi: 10.3390/foods6100092.
[42] L. L. Li et al., “Pharmacokinetics and tissue distribution of gingerols and shogaols from ginger (zingiber
officinale rosc.) in rats by UPLCQ-Exactive–HRMS,” Molecules, vol. 24, no. 3, pp. 112, 2019, doi:
10.3390/molecules24030512.
[43] S. K. Sanwal, R. K. Yadav, P. K. Singh, J. Buragohain, and M. R. Verma, “Gingerol content of different
genotypes of ginger (Zingiber officinale),” Indian J. Agric. Sci., vol. 80, no. 3, pp. 258260, 2010.
[44] T. Chumroenphat, I. Somboonwatthanakul, L. Butkhup, and S. Saensouk, “6-gingerol content of ginger
(Zingiber officinale Roscoe) by different drying metthods,” Bot. Res. Trop. Asia, no. October, p. , 2015.
[45] N. Puvača et al., “Bioactive Compounds of Garlic, Black Pepper and Hot Red Pepper,” XVI Int. Symp. “Feed
Technol. Food Tech Congr., no. October, pp. 116122, 2014, doi: 10.13140/2.1.1833.9526.
[46] A. Shang et al., “Bioactive compounds and biological functions of garlic (allium sativum L.),” Foods, vol. 8,
no. 7, pp. 131, 2019, doi: 10.3390/foods8070246.
[47] I. C. F. R. F. Natalia Martins, Spyridon Petropoulos, “Chemical composition and bioactive compounds of
garlic (,” Thesis Rev., pp. 142, 2016.
[48] S. Ravichandran et al., “Pharmacophore model of the quercetin binding site of the SIRT6 protein,” J. Mol.
Graph. Model., vol. 49, pp. 3846, 2014, doi: 10.1016/j.jmgm.2014.01.004.
[49] S. Soewono, Suhartati; Khaerunnisa, Flavonoid. Surabaya: Airlangga University Press, 2016.
[50] N. Aziz, M. Y. Kim, and J. Y. Cho, “Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and
in silico studies,” J. Ethnopharmacol., vol. 225, no. May, pp. 342358, 2018, doi: 10.1016/j.jep.2018.05.019.
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 March 2020 doi:10.20944/preprints202003.0226.v1
... At the same time, garlic compounds target the main protease of SARS-CoV-2, preventing protein maturation and halting the propagation of the infectious process, thereby enhancing the body's resistance to the virus (Thuy et al., 2020). Similarly, quercetin, found in purple onion (Allium cepa), inhibits the Mpro protease, including the PDB6LU7 protein (Khaerunnisa et al., 2020). Curcumin, considered a functional food, has garnered increasing interest due to its antioxidant, antiinflammatory, and antiviral properties (Sanidad et al., 2019;Barquero, 2020), including its ability to inhibit the endoribonuclease Nsp15, which is encoded by MERS-CoV (Barquero, 2020). ...
... Garlic (Allium sativum L.) ECA2 inhibition; It attacks the PDB6LU7 protein, preventing protein maturation and the spread of the infectious process. Thuy et al. (2020) Purple onion (Allium cepa) Quercetin in onion inhibits protease (M pro ) including PDB6LU7 Khaerunnisa et al. (2020) Curcumin Inhibition of non-structural protein 15 (Nsp15) Barquero (2020) Cerasus avium L. ...
Article
Full-text available
With the onset of the COVID-19 pandemic, coupled with the low availability of medicines and vaccines with proven efficacy, there was a growing impact on public health, followed by inconsistencies from both an economic and social perspective, due to the declaration of the "State of Emergency" and the adoption of strict sanitary control measures, which also contributed to the progression of food insecurity. In this context, the search for natural methods for the prevention and control of symptoms gained prominence, with functional foods and bee products being highlighted due to their bioactive compounds, which are capable of modulating metabolic processes and acting as antioxidants, anti-inflammatories, anti-infectives, and antivirals. The aim of this study was to review natural strategies with antiviral and anti-COVID properties across various databases. A comprehensive review of functional foods, bee products, and biotechnology was conducted in scientific article and patent databases, with no time constraints. Among the findings, several functional foods, natural products, and bee products exhibited significant antiviral, anti-inflammatory, and immunomodulatory activities against coronaviruses, highlighting the critical role of food in human health. Additionally, these findings represent a promising strategy for the food industry in the development of biopreservatives, functional foods, and organic products for both human and animal health.
... Following endocytosis, the gRNA is translated into non-functional polypeptides, which the Mpro/3CL PRO and PLPro enzymes' proteolytic activity cleaves into functional proteins. The main protease, Mpro/3CL PRO enzyme, has been shown to be inhibited by, 6-gingerol, humulene epoxide, isotine, hesperidin, seselin, feralolide catechin, epicatechin gallate (ECG), EGCG, curcumin, quercetin, and kaempferol (Amparo et al. 2021;Khaerunnisa et al. 2020;Nivetha et al. 2021); however, 6-gingerol and humulene epoxide inhibited the PLPro enzyme (Amparo et al. 2021), leading to proteolysis inhibition and non-infective non-functional proteins. Furthermore, 6LU7 and 7JTL, which are necessary for the proteolysis pathway, were blocked by guaiol and gingerenone A (Pandey et al. 2021). ...
... Moreover, curcumin and 6-gingerol hinder the replication process (Khaerunnisa et al. 2020). The assembly of genomic RNA and proteins, as well as the initiation of the exocytosis pathway, causes the host cell to undergo apoptosis after translation and post-translational maturation. ...
... Initial research has suggested that a combination of lopinavir and ritonavir may have inhibitory effects on the virus, with numerous other antiviral medications also under investigation [8,9]. Additionally, the potential therapeutic benefits of naturally occurring bioactive flavonoid molecules have been explored due to their diverse bioactivity and low toxicity [10,11]. The SARS-CoV-2 virus, a positive-sense singlestranded RNA virus, encompasses a plethora of structural proteins such as accessory proteins and spike glycoprotein, in addition to several non-structural proteins encoded by its viral genome. ...
... Targeting this enzyme with antiviral medications has shown promise in preventing viral replication by limiting the activity of Mpro and subsequently reducing the quantity of virus particles [15][16][17]. Among these medications, certain HIV-1 protease inhibitors like lopinavir and ritonavir have exhibited effectiveness in hindering SARS-CoV-2 from producing its major protease, presenting potential therapeutic avenues against COVID-19 [10]. ...
Article
Full-text available
Background Since December 2019, a global crisis has unfolded with the emergence of a new strain of coronavirus known as SARS-CoV-2. This pandemic has afflicted hundreds of millions of people worldwide, resulting in millions of fatalities. In response to this urgent healthcare crisis, extensive efforts have been made to discover inhibitors of the COVID-19 virus. Given the structural similarities between SARS-CoV-2 and HCV, drugs approved by the FDA for treating HCV were selected and subjected to in silico testing against the SARS-CoV-2 virus, with Remdesivir used as the standard for validation. Drug repurposing and phytochemical testing have also been conducted to identify potential candidates capable of inhibiting or suppressing the infection caused by the coronavirus. The time constraints imposed by the pandemic necessitated the in silico analysis of existing drug molecules against the coronavirus. Eleven HCV drugs approved by the FDA, along with one RNA synthesis inhibitor antibiotic drug, were tested using the in silico method due to their structural similarities with HCV and the SARS-CoV-2 virus. Results Molecular docking and MD simulation studies were performed for all selected compounds. Binding energies, root-mean-square deviation, root-mean-square fluctuation, solvent-accessible surface area, radius of gyration, and molecular mechanics generalized born surface area were calculated. Based on docking and MD simulation studies all the selected compounds have shown good binding energy values with Mpro (PDB ID: 6LU7). No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA. Conclusions This study shows that FDA-approved HCV drugs can be used as for SARS-COVID-19 inhibitors.
... The 2D interaction diagrams of erlotinib with AR, ESR-1, and EGFR are depicted in (Fig. S2) in the supplementary materials. While the number of interactions between the amino acid residues and a compound does not necessarily reflect its true pharmacological activity as the type, the strength of interactions and their inter-site distances play a crucial role in stabilizing the ligand-protein complex which in turn affects its binding affinity (Khaerunnisa, 2020). That could explain the lower docking score of ismine (16) when bound to EFGR compared to ESR-1 despite possessing a higher number of interactions. ...
Article
Full-text available
Non-small cell lung cancer (NSCLC) is a widespread highly malignant type of lung cancer. Conventional chemotherapeutic drugs may be accompanied by both drug resistance and serious side effects in patients. Therefore, safer and more effective medications are urgently needed for the treatment of NSCLC. This study investigates the mode of action of 21 phytoconstituents previously isolated from the Amaryllidaceous plants Crinum bulbispermum (Burm.f.), Pancratium maritimum L., and Hippeastrum vittatum Herbert alongside the Asteraceous plant Centaurea scoparia Sieb. for therapy of NSCLC via in vitro cytotoxic, network pharmacology, and molecular docking analyses. Despite the in vitro and in vivo cytotoxic studies carried out on phytoconstituents from these plants in treating numerous cancer types, scarce information documenting their cytotoxic activity towards NSCLC cells is available. First, the compounds were tested for their in vitro cytotoxic activities and selectivity on human non-small cell lung cancer cells using disk diffusion assay. Compounds having significant potencies were promoted for network pharmacology analysis. Pharm mapper, Genecards, STRING, and KEGG databases were utilized for surfing target genes and pathways for these compounds, while for construction of compound-target-pathway (C-T-P) network, Cytoscape 3.7.1. freeware was used. Molecular docking and dynamics simulation were run for the top hit constituents against the most enriched molecular targets followed by in silico ADMET studies using Schrodinger® suite and Gromacs. In vitro cytotoxicity testing demonstrated that crinamine was the most potent compound followed by lycorine, hemanthidine, and haemanthamine. The network pharmacology approach revealed the enrichment of acetyllycoramine, pluviine, 5-hydroxy-7-methoxy-2-methylchromone, and ismine. Whereas, androgen receptor (AR), epidermal growth factor receptor (EGFR), and estrogen-sensitive receptor alpha (ESR1) were the most enriched target genes. Pathway analysis revealed that central carbon metabolism, EGFR tyrosine kinase inhibitor endocrine resistance, and non-small cell lung cancer were the most enriched cancer-related pathways. Ismine possessed the most stable ligand-protein interactions when docked to the three proteins, with MD simulations further confirming its strong and consistent binding to AR, moderate stability with ESR-1, and lower stability with EGFR over the 100 ns trajectory. ADMET study conducted on the above compounds confirmed their excellent drug-likeness properties, oral bioavailability, and safety profiles highlighting the need for some structural modifications to pluviine to enhance its oral bioavailability. These integrated approaches showed that some constituents from the investigated plants interact synergistically against non-small cell lung cancer-related genes and pathways.
... et Zucc.) fruit [41], Artabotrys hexapetalus stembark and leaf [42], and Artabotrys suaveolens stembark and leaf extracts [43]; as well as potential main protease inhibitors of COVID-19 or SARS-Cov-2 virus [44,45]. ...
Article
Full-text available
One way to treat diabetes mellitus type II is by using α-glucosidase inhibitor, that will slow down the postprandial glucose intake. Metabolomics analysis of Artabotrys sumatranus leaf extract was used in this research to predict the active compounds as α-glucosidase inhibitors from this extract. Both multivariate statistical analysis and machine learning approaches were used to improve the confidence of the predictions. After performance comparisons with other machine learning methods, random forest was chosen to make predictive model for the activity of the extract samples. Feature importance analysis (using random feature permutation and Shapley score calculation) was used to identify the predicted active compound as the important features that influenced the activity prediction of the extract samples. The combined analysis of multivariate statistical analysis and machine learning predicted 9 active compounds, where 6 of them were identified as mangiferin, neomangiferin, norisocorydine, apigenin-7-O-galactopyranoside, lirioferine, and 15,16-dihydrotanshinone I. The activities of norisocorydine, apigenin-7-O-galactopyranoside, and lirioferine as α-glucosidase inhibitors have not yet reported before. Molecular docking simulation, both to 3A4A (α-glucosidase enzyme from Saccharomyces cerevisiae, usually used in bioassay test) and 3TOP (a part of α-glucosidase enzyme in human gut) showed strong to very strong binding of the identified predicted active compounds to both receptors, with exception of neomangiferin which only showed strong binding to 3TOP receptor. Isolation based on bioassay guided fractionation further verified the metabolomics prediction by succeeding to isolate mangiferin from the extract, which showed strong α-glucosidase activity when subjected to bioassay test. The correlation analysis also showed a possibility of 3 groups in the predicted active compounds, which might be related to the biosynthesis pathway (need further research for verification). Another result from correlation analysis was that in general the α-glucosidase inhibition activity in the extract had strong correlation to antioxidant activity, which was also reflected in the predicted active compounds. Only one predicted compound had very low positive correlation to antioxidant activity.
... According to the study on molecular docking of potential COVID-19 main protease inhibitors, performed using Auto dock 4.2, with Lamarckian Genetic Algorithm, some of the compounds such as demethoxycurcumin, oleuropein, and curcumin which are the main bioactive components of C. caesia, have the best potential to act as COVID-19 main protease inhibitors. The binding energies obtained from the docking of 6LU7 with demethoxycurcumin, oleuropein, and curcumin were −7.99, −7.31, and −7.05 kcal/mol respectively [73]. ...
Article
Full-text available
Medicinal plants are well-known for their bioactive compounds, with various parts possessing distinct medicinal properties. One such medicinal plant is Curcuma caesia Roxb., commonly known as Black turmeric, and is popular among ethnic groups in Nepal and India because of its diverse medicinal values. Researchers are exploring this hidden talent and have identified components such as camphor, 1, 8 Cineole, ar-curcumene, β-elemene, borneol, bornyl acetate, and α-terpineol as major phytochemicals. The rhizomes and leaves of this plant have demonstrated antibacterial, antioxidant, anticancer, and anti-inflammatory properties attributed to their bioactive phytochemicals. C. caesia, with its unique properties, can emerge as a potential alternative to various synthetic drugs used in wound treatment, cancer therapy, bacterial infections, and immune system enhancement. This study aims to shed light on the recognition of this valuable plant, which is still hidden in the soils of Nepal and India. This article compiles various research findings on the medicinal properties of the phytochemicals found in C. caesia. It explores the potential applications of this plant using advanced technologies leading to economic growth within the field of medicine.
... The bioactive compounds such as abietane-type (1-8) and labdane-type diterpenes, sesquiterpenes, lupane-type triterpenes, lignoids, and curcumin have shown anti-SARS-CoV activity in the µM range [317]. Their inhibitory activity against COVID-19 has been documented in a molecular docking study [319]. ...
... To take only the example of flavonoids here, let's say that quercetin, rutin, naringin, and apigenin, found in several species used in recipes, are recognized and sought after for their antiviral, antibacterial, and anti-inflammatory properties. A study using computational analysis has suggested that various flavonoids, such as kaempferol, quercetin, luteolin-7-glucoside, apigenin-7-glucoside, naringenin, catechin, and epigallocatechin, may hold significance as potential inhibitors of the SARS-CoV-2 M pro [126]. Another study found that quercetin may be effective in treating early-stage COVID-19. ...
Article
Full-text available
The use of medicinal herbs is highly developed in Haiti. However, there is a significant lack of knowledge in the literature on medicinal plants and their uses. The objective of this study was to determine the knowledge and practices of Haitian families for the prevention/treatment of COVID-19, influenza, and respiratory diseases, as well as the mode of preparation and administration of the plants. Individuals were interviewed using the TRAMIL questionnaire as the information holder. The data obtained were analyzed by calculating 5 indices (relative frequency of citation, use value, the family use value, informant consensus factor, and fidelity level). The study surveyed 120 Haitians and collected 75 plants from 43 botanical families. The botanical family most used for all these preventions and remedies is the Lamiaceae. The highest ranked species with a relative frequency of citation value > 0.3. Infusion, decoction, and in the form of punch are the methods used for the remedies. The study found that the use of herbal remedies is still prevalent in the study area, and many of the commonly used plants have been scientifically validated. However, some plants, such as Samyda rosea Sims, lack sufficient research and are recommended for further investigation.
Article
The COVID-19 pandemic has spurred global efforts to identify effective therapeutic strategies. One promising avenue involves exploration of bioactive metabolites as potential inhibitors of main protease enzyme (Mpro) of SARS-CoV-2 virus. Mpro plays a critical role in viral replication and is considered a prime target for drug development.This review delves in potential of bioactive metabolites in managing COVID-19 by inhibiting Mpro. Bioactive metabolites are naturally occurring compounds found in various organisms, including plants, fungi, and marine life, known for their diverse biological activities. They have shown promise in inhibiting enzymatic activity of Mpro, disrupt viral replication-mitigate infection. This study explores a wide range of bioactive, sources, and inhibitory effects on Mpro. It investigates mechanisms of action and binding affinities of these metabolites, shedding light on their potential as anti-COVID-19 agents. Moreover, the review discusses the development of bioactive metabolite-based drugs and their safety and efficacy in COVID-19 management. By elucidating the potential of metabolites in inhibiting Mpro, this review contributes to the development of novel therapeutic interventions for COVID-19, offering hope in the battle against ongoing pandemic. These findings may pave the way for development of effective treatments that can complement existing strategies in the fight against SARS-CoV-2.
Article
Boosting the immune system has become a crucial aspect in the global battle against the COVID-19 pandemic and other similar infections to protect oneself against symptoms, especially in the prevention of viral infections of the lower respiratory tract. The importance of conducting more studies to create successful herbal formulations as infection prevention measures is emphasized in this review, which looks at the function of immune-boosting nutrients, medicinal plants, and herbal treatments. We reviewed and analyzed 207 studies published from 1946 to the present using reputable databases like Google Scholar, PubMed, and NCBI. The review examined 115 plant species in total and identified 12 key nutrients, including vitamins A, D, C, omega-3 fatty acids, iron, and zinc, while noting that four plant families, Rosaceae, Asteraceae, Amaryllidaceae, and Acanthaceae, show potential against respiratory infections like influenza, RSV, and SARS-CoV. To lower the risk of infection, it is recommended to consume nutritious meals that have immune-modulating qualities. Information on the bioactive components of medicinal herbs, spices, and plants that have been effective in treating respiratory viral infections and related conditions is compiled in this review, which highlights phytoactive substances with antibacterial and antiviral activity as effective modulators to lower the risk of infections. Furthermore, it is highlighted that ancient knowledge systems, like Ayurveda and Naturopathy, should be integrated to help develop new herbal formulations. To improve immunity and lessen vulnerability to serious respiratory infections, the results highlight the need for including immune-modulating foods and plant-based medicines into everyday routines.
Article
Full-text available
After the outbreak of the severe acute respiratory syndrome (SARS) in the world in 2003, human coronaviruses (HCoVs) have been reported as pathogens that cause severe symptoms in respiratory tract infections. Recently, a new emerged HCoV isolated from the respiratory epithelium of unexplained pneumonia patients in the Wuhan seafood market caused a major disease outbreak and has been named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus causes acute lung symptoms, leading to a condition that has been named as “coronavirus disease 2019” (COVID-19). The emergence of SARS-CoV-2 and of SARS-CoV caused widespread fear and concern and has threatened global health security. There are some similarities and differences in the epidemiology and clinical features between these two viruses and diseases that are caused by these viruses. The goal of this work is to systematically review and compare between SARS-CoV and SARS-CoV-2 in the context of their virus incubation, originations, diagnosis and treatment methods, genomic and proteomic sequences, and pathogenic mechanisms.
Article
Full-text available
There were severe panics caused by Severe Acute Respiratory Syndrome (SARS) and Middle-East Respiratory Syndrome-Coronavirus. Therefore, researches targeting these viruses have been required. Coronaviruses (CoVs) have been rising targets of some flavonoids. The antiviral activity of some flavonoids against CoVs is presumed directly caused by inhibiting 3C-like protease (3CLpro). Here, we applied a flavonoid library to systematically probe inhibitory compounds against SARS-CoV 3CLpro. Herbacetin, rhoifolin and pectolinarin were found to efficiently block the enzymatic activity of SARS-CoV 3CLpro. The interaction of the three flavonoids was confirmed using a tryptophan-based fluorescence method, too. An induced-fit docking analysis indicated that S1, S2 and S3′ sites are involved in binding with flavonoids. The comparison with previous studies showed that Triton X-100 played a critical role in objecting false positive or overestimated inhibitory activity of flavonoids. With the systematic analysis, the three flavonoids are suggested to be templates to design functionally improved inhibitors.
Article
Full-text available
Fruit and vegetable intake has been associated with a reduced risk of cardiovascular disease. Quercetin and kaempferol are among the most ubiquitous polyphenols in fruit and vegetables. Most of the quercetin and kaempferol in plants is attached to sugar moieties rather than in the free form. The types and attachments of sugars impact bioavailability, and thus bioactivity. This article aims to review the current literature on the bioavailability of quercetin and kaempferol from food sources and evaluate the potential cardiovascular effects in humans. Foods with the highest concentrations of quercetin and kaempferol in plants are not necessarily the most bioavailable sources. Glucoside conjugates which are found in onions appear to have the highest bioavailability in humans. The absorbed quercetin and kaempferol are rapidly metabolized in the liver and circulate as methyl, glucuronide, and sulfate metabolites. These metabolites can be measured in the blood and urine to assess bioactivity in human trials. The optimal effective dose of quercetin reported to have beneficial effect of lowering blood pressure and inflammation is 500 mg of the aglycone form. Few clinical studies have examined the potential cardiovascular effects of high intakes of quercetin- and kaempferol-rich plants. However, it is possible that a lower dosage from plant sources could be effective due to of its higher bioavailability compared to the aglycone form. Studies are needed to evaluate the potential cardiovascular benefits of plants rich in quercetin and kaempferol glycoside conjugates.
Article
Full-text available
Garlic (Allium sativum L.) is a widely consumed spice in the world. Garlic contains diverse bioactive compounds, such as allicin, alliin, diallyl sulfide, diallyl disulfide, diallyl trisulfide, ajoene, and S-allyl-cysteine. Substantial studies have shown that garlic and its bioactive constituents exhibit antioxidant, anti-inflammatory, antibacterial, antifungal, immunomodulatory, cardiovascular protective, anticancer, hepatoprotective, digestive system protective, anti-diabetic, anti-obesity, neuroprotective, and renal protective properties. In this review, the main bioactive compounds and important biological functions of garlic are summarized, highlighting and discussing the relevant mechanisms of actions. Overall, garlic is an excellent natural source of bioactive sulfur-containing compounds and has promising applications in the development of functional foods or nutraceuticals for the prevention and management of certain diseases.
Article
Full-text available
The olive orchard cultivation in Mediterranean countries results in huge amounts of lignocellulosic biomass residues. One of the main residues are olive leaves. Olive leaves contain high concentrations of bioactive antioxidant compounds like oleuropein and luteolin-7-glucoside. The production of biactive compounds from olive leaves requires treatments capable of breaking the lignocellulosic structure. Current research focuses on use of inexpensive, quick, and not harmful to the environment treatments, searching a more simplified large-scale operation approach. Recently, advances in applied chemistry have led to possible new emerging industrial techniques like ultrasound-assisted extraction (UAE). This technology is a promising candidate as a green treatment solution for olive leaves utilization in a biorefinery. However, this application goes through prior optimization of technique and operating conditions. The goal of this study was to optimize the extraction of oleuropein and luteolin-7-glucoside from olive leaves through an investigation of the influence of key factors of ultrasound-assisted extraction using an experimental central composite design, in comparison with conventional Soxhlet extraction. The highest extraction efficiency and antioxidant capacity were obtained under optimal increment of temperature and amplitude conditions (40 °C and 30%, respectively). Values for oleuropein, luteolin-7-glucoside were 69.91 g/kg and 1.82 g/kg, respectively.
Article
Full-text available
Olive leaf extracts are of special interest due to their proven therapeutic effects. However, they are still considered a by-product of the table olive and the oil industries. In order to learn possible ways of exploiting this waste for health purposes, we investigated the phytochemical profiles and antioxidant activities in the leaves of 15 Italian Olea europaea L. cultivars grown in the same pedoclimatic conditions. The phenolic profiles and amounts of their seven representative compounds were analyzed using HPLC ESI/MS-TOF. The antioxidant activities were determined using three different antioxidant assays (DPPH, ORAC, and superoxide anion scavenging assay). Wide ranges of total phenolic content (11.39-48.62 g GAE kg −1 dry weight) and antioxidant activities (DPPH values: 8.67-29.89 µmol TE mg −1 dry weight, ORAC values: 0.81-4.25 µmol TE mg −1 dry weight, superoxide anion scavenging activity values: 27.66-48.92 µmol TE mg −1 dry weight) were found in the cultivars. In particular, the cultivars Itrana, Apollo, and Maurino, showed a high amount of total phenols and antioxidant activity, and therefore represent a suitable natural source of biological compounds for use in terms of health benefits.
Article
Full-text available
In the herbal pharmacopeia Indonesia, curcumin is used as a marker compound in the temulawak extract. In this study, we analyzed the contents and profiles of curcuminoid constituent in temulawak extracts from three centers for the development of medicinal plants in Central Java, Indonesia; i.e Semarang Regency, Semarang City, and Karanganyar Regency. The results showed that the extracts of temulawak have yields ranging from 8.25 - 14.90% and the highest yield was obtained in the sample from one of the farmers in Semarang (B1). Meanwhile, total curcuminoid is ranging from 8.70-11.50% and the highest value belongs to sample grown in Semarang (B1 and B2, in the average levels of 11.50% and 11.30%). Variations in the composition of the curcuminoid constituent showed that curcumin is the main component in all samples. The relative contents of these compounds ranged from 68 to 76%, while the demethoxycurcuminis and bisdemethoxycurcuminis were found in the range of 23 to 29%, and from 1 to 3%, respectively.
Article
Full-text available
Proteases are a major enzyme group playing important roles in a wide variety of biological processes in life forms ranging from viruses to mammalians. The aberrant activity of proteases can lead to various diseases; consequently, host proteases have been the focus of intense investigation as potential therapeutic targets. A wide range of viruses encode proteases which play an essential role in viral replication and, therefore, constitute attractive targets for the development of antiviral therapeutics. There are numerous examples of successful drug development targeting cellular and viral proteases, including antivirals against human immunodeficiency virus and hepatitis C virus. Most FDA-approved antiviral agents are peptidomimetics and macrocyclic compounds that interact with the active site of a targeted protease. Norovirus proteases are cysteine proteases that contain a chymotrypsin-like fold in their 3D structures. This review focuses on our group’s efforts related to the development of norovirus protease inhibitors as potential anti-norovirus therapeutics. These protease inhibitors are rationally designed transition-state inhibitors encompassing dipeptidyl, tripeptidyl and macrocyclic compounds. Highly effective inhibitors validated in X-ray co-crystallization, enzyme and cell-based assays, as well as an animal model, were generated by launching an optimization campaign utilizing the initial hit compounds. A prodrug approach was also explored to improve the pharmacokinetics (PK) of the identified inhibitors.
Article
An outbreak of novel coronavirus (2019-nCoV) that began in Wuhan, China, has spread rapidly, with cases now confirmed in multiple countries. We report the first case of 2019-nCoV infection confirmed in the United States and describe the identification, diagnosis, clinical course, and management of the case, including the patient's initial mild symptoms at presentation with progression to pneumonia on day 9 of illness. This case highlights the importance of close coordination between clinicians and public health authorities at the local, state, and federal levels, as well as the need for rapid dissemination of clinical information related to the care of patients with this emerging infection.
Article
As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), abidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments.